- Time:
Chimeric antigen receptor T (CAR-T) cells are promising treatments for hematologic and solid malignancies. CAR-T cells can recognize and eliminate neoplastic cells expressing specific protein antigens. However, the current generation of CAR-T cells cannot distinguish between neoplastic and normal cells that may also be expressing the same antigen, thus potentially resulting in “on-target/off-tumor” toxicity. In this GEN webinar, we will review the RNAscope® in situ hybridization (ISH) method and show applications of the technology in the CAR-T cell and immuno-oncology fields. We will demonstrate how RNAscope ISH can be utilized to identify novel CAR-T cell targets and subsequently qualify monoclonal antibodies directed against those targets for immunohistochemistry. We will show how ISH can be used to predict CAR-T cell target organ toxicity in preclinical models. Finally, we will discuss optimal preparation of tissues, cell pellets, and cytospin slides for evaluation by ISH.
You Will Learn
- How RNAscope ISH technology can streamline your target identification and selection workflows
- The advantages of using ISH for immunotherapeutic target cell selection
- How ISH evaluation of target expression in normal tissues can be used to predict CAR-T cell induced toxicity
- Optimal tissue, cell pellet, and cytospin slide preparation for RNAscope ISH
Produced with support from:
Panelists
James B. Rottman, D.V.M., Ph.D., D.A.C.V.P.
Senior Director of Translational Development,
Bluebird Bio
Courtney Anderson, Ph.D.
Group Leader Applications,
Advanced Cell Diagnostics
